Lipella Pharmaceuticals

Update in progress

LIPO (OTC Markets OTCPK)

Lipella Pharmaceuticals is a clinical-stage biotechnology company that develops drugs by reformulating active agents from existing generic medicines and optimizing these reformulations for new uses. Its product family includes LP-10 (tacrolimus for radiation-induced hemorrhagic cystitis), LP-310 (tacrolimus for oral lichen planus), LP-410 (oral liposomal tacrolimus for oral graft-versus-host disease), and LP-50 (intravesical immunoglobulins for non-muscle invasive bladder cancer). Incorporated in 2005 and based in Pittsburgh, PA, Lipella filed for Chapter 11 bankruptcy on March 30, 2026.